Molecular targets of antihypertensive peptides: Understanding the mechanisms of action based on the pathophysiology of hypertension

International Journal of Molecular Sciences

Volumn 16, Issue 1, 2014, Pages 256-283

  Majumder, Kaustav ^a   Wu, Jianping ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

Author keywords

Angiotensin converting enzyme; Antihypertensive peptides; Endothelin; Hypertension; Nitric oxide; Spontaneously hypertensive rats

Indexed keywords

ANGIOTENSIN II; ENDOTHELIAL NITRIC OXIDE SYNTHASE; ENDOTHELIN A RECEPTOR; ENDOTHELIN B RECEPTOR; FOOD PROTEIN DERIVED ANTIHYPERTENSIVE PEPTIDE; MATRIX METALLOPROTEINASE; MILK PROTEIN; OVALBUMIN; OVOTRANSFERRIN; PEPTIDE; PROTEIN HYDROLYSATE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; ANTIHYPERTENSIVE AGENT; CASEIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; PEPTIDE FRAGMENT; PROTEIN INTAKE;

ADRENERGIC SYSTEM; ARTICLE; BLOOD PRESSURE REGULATION; DIASTOLIC BLOOD PRESSURE; ENDOTHELIAL DYSFUNCTION; HUMAN; HYPERTENSION; INFLAMMATION; META ANALYSIS (TOPIC); MOLECULARLY TARGETED THERAPY; NONHUMAN; OXIDATIVE STRESS; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL (TOPIC); RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SYSTOLIC BLOOD PRESSURE; VASOCONSTRICTION; ANIMAL; PHARMACOLOGY; PROTEIN INTAKE; THERAPEUTIC USE;

ANIMALIA; RATTUS;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; ANTIHYPERTENSIVE AGENTS; CASEINS; DIETARY PROTEINS; HUMANS; HYPERTENSION; PEPTIDE FRAGMENTS;

EID: 84919795223     PISSN: 16616596     EISSN: 14220067     Source Type: Journal    
DOI: 10.3390/ijms16010256     Document Type: Article

References (154)

1. WHO. A Global Brief on Hypertension, Silent Killer, Global Public Health Crisis; WHO: Geneva, Switzerland, 2013.
2. Public Health Agency of Canada. Tracking Heart Disease and Stroke in Canada—Stroke Highlights 2011; Public Health Agency of Canada: Ottawa, ON, Canada, 2011.
3. Moser, M.; Franklin, S.S. Hypertension Management: Results of a New National Survey for the Hypertension Education Foundation: Harris Interactive. J. Clin. Hypertens. (Greenwich) 2007, 9, 316-323.
4. Williams, B.; Poulter, N.R.; Brown, M.J.; Davis, M.; McInnes, G.T.; Potter, J.F.; Sever, P.S.; Thom, S.M. Guidelines for Management of Hypertension: Report of the Fourth Working Party of the British Hypertension Society, 2004—BHSIV. J. Hum. Hypertens. 2004, 18, 139-185.
5. Klag, M.J.; Whelton, P.K.; Randall, B.L.; Neaton, J.D.; Brancati, F.L.; Ford, C.E.; Shulman, N.B.; Stamler, J. Blood Pressure and End-Stage Renal Disease in Men. N. Engl. J. Med. 1996, 334, 13-18.
6. De las Heras, N.; Ruiz-Ortega, M.; Ruperez, M.; Sanz-Rosa, D.; Miana, M.; Aragoncillo, P.; Mezzano, S.; Lahera, V.; Egido, J.; Cachofeiro, V. Role of Connective Tissue Growth Factor in Vascular and Renal Damage Associated with Hypertension in Rats. Interactions with Angiotensin II. J. Renin Angiotensin Aldosterone Syst. 2006, 7, 192-200.
7. Perazella, M.A.; Setaro, J.F. Renin-Angiotensin-Aldosterone System: Fundamental Aspects and Clinical Implications in Renal and Cardiovascular Disorders. J. Nucl. Cardiol. 2003, 10, 184-196.
8. Alexander, R.W. Hypertension and the Pathogenesis of Atherosclerosis: Oxidative Stress and the Mediation of Arterial Inflammatory Response: A New Perspective. Hypertension 1995, 25, 155-161.
9. Altman, R. Risk Factors in Coronary Atherosclerosis Athero-Inflammation: The Meeting Point. Thromb. J. 2003, 1, 4.
10. US Department of Health & Human Services. HHS Secretary Sebelius Statement on National High Blood Pressure Education Month; US Department of Health & Human Services: Washington, DC, USA, 2012.
11. Atkinson, A.B.; Robertson, J.I.S. Captopril in the Treatment of Clinical Hypertension and Cardiac-Failure. Lancet 1979, 2, 836-839.
12. Gavras, H.; Gavras, I. Angiotensin Converting Enzyme Inhibitors. Properties and Side Effects. Hypertension 1988, 11, II37.
13. Chobanian, A.V.; Bakris, G.L.; Black, H.R.; Cushman, W.C.; Green, L.A.; Izzo, J.L.; Jones, D.W.; Materson, B.J.; Oparil, S.; Wright, J.T., et al. Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 2003, 42, 1206-1252.
14. Vaughan, C.J.; Delanty, N. Hypertensive Emergencies. Lancet 2000, 356, 411-417.
15. Stephanie, J.; Suhad, S.A.; Peter, J.H.J. Evolution of the Human Diet: Linking our Ancestral Diet to Modern Functional Foods as a Means of Chronic Disease Prevention. J. Med. Food 2009, 12, 925-934.
16. Miguel, M.G.; Maria, B.R.; Lluis, S.M.; Denis, L.; Ramón, E.; Antonia, T. Mediterranean Food Pattern and the Primary Prevention of Chronic Disease: Recent Developments. Nutr. Rev. 2009, 67, S111-S116.
17. Mozaffarian, D.; Hao, T.; Rimm, E.B.; Willett, W.C.; Hu, F.B. Changes in Diet and Lifestyle and Long-Term Weight Gain in Women and Men. N. Engl. J. Med. 2011, 364, 2392-2404.
18. Craddick, S.R.; Elmer, P.J.; Obarzanek, E.; Vollmer, W.M.; Svetkey, L.P.; Swain, M.C. The DASH Diet and Blood Pressure. Curr. Atheroscler. Rep. 2003, 5, 484-491.
19. Rouse, I.; Armstrong, B.; Beilin, L.J.; Vandongen, R. Blood-Pressure-Lowering Effect of a Vegetarian Diet: Controlled Trial in Normotensive Subjects. Lancet 1983, 321, 5-10.
20. Doaei, S.; Gholamalizadeh, M. The Association of Genetic Variations with Sensitivity of Blood Pressure to Dietary Salt: A Narrative Literature Review. ARYA Atheroscler. 2014, 10, 169-174.
21. Stolarz-Skrzypek, K.; Bednarski, A.; Czarnecka, D.; Kawecka-Jaszcz, K.; Staessen, J.A. Sodium and Potassium and the Pathogenesis of Hypertension. Curr. Hypertens. Rep. 2013, 15, 122-130.
22. Aaron, K.J.; Sanders, P.W. Role of Dietary Salt and Potassium Intake in Cardiovascular Health and Disease: A Review of the Evidence. Mayo Clin. Proc. 2013, 88, 987-995.
23. Rebholz, C.M.; Friedman, E.E.; Powers, L.J.; Arroyave, W.D.; He, J.; Kelly, T.N. Dietary Protein Intake and Blood Pressure: A Meta-Analysis of Randomized Controlled Trials. Am. J. Epidemiol. 2012, 176 (Suppl. S7), S27-S43.
24. Carey, V.J.; Bishop, L.; Charleston, J.; Conlin, P.; Erlinger, T.; Laranjo, N.; McCarron, P.; Miller, E.; Rosner, B.; Swain, J., et al. Rationale and Design of the Optimal Macro-Nutrient Intake Heart Trial to Prevent Heart Disease (OMNI-Heart). Clin. Trials 2005, 2, 529-537.
25. Miller, E.R., 3rd; Erlinger, T.P.; Appel, L.J. The Effects of Macronutrients on Blood Pressure and Lipids: An Overview of the DASH and OmniHeart Trials. Curr. Atheroscler. Rep. 2006, 8, 460-465.
26. Hartmann, R.; Meisel, H. Food-Derived Peptides with Biological Activity: From Research to Food Applications. Curr. Opin. Biotechnol. 2007, 18, 163-169.
27. Miguel, M.; Aleixandre, A. Anti Hypertensive Peptides Derived from Egg Proteins. J. Nutr. 2006, 136, 1457-1460.
28. Torruco-Uco, J.G.; Dominguez-Magana, M.A.; Davila-Ortiz, G.; Martinez-Ayala, A.; Chel-Guerrero, L.A.; Betancur-Ancona, D.A. Antihypertensive Peptides, an Alternative for Treatment of Natural Origin: A Review. Cienc. Tecnol. Aliment. 2008, 6, 158-168.
29. Martinez-Maqueda, D.; Miralles, B.; Recio, I.; Hernandez-Ledesma, B. Antihypertensive Peptides from Food Proteins: A Review. Food Funct. 2012, 3, 350-361.
30. Peah, M. Renin-Angiotensin System—Biochemistry and Mechanisms of Action. Physiol. Rev. 1977, 57, 313-370.
31. Zaman, M.; Oparil, S.; Calhoun, D. Drugs Targeting the Renin-Angiotensin-Aldosterone System. Nat. Rev. Drug Discov. 2002, 1, 621-636.
32. Akpaffiong, M.J.; Taylor, A.A. Antihypertensive and Vasodilator Actions of Antioxidants in Spontaneously Hypertensive Rats. Am. J. Hypertens. 1998, 11, 1450-1460.
33. De Ciuceis, C.; Porteri, E.; Rizzoni, D.; Rezzani, R.; Rodella, L.F.; Boari, G.E.; Tengattini, S.; Bonomini, F.; Rizzardi, N.; Platto, C., et al. Antioxidant Treatment with Melatonin and Pycnogenol may Improve the Structure and Function of Mesenteric Small Arteries in Spontaneously Hypertensive Rats. Hypertension 2009, 54, E119-E119.
34. Davalos, A.; Miguel, M.; Bartolome, B.; Lopez-Fandino, R. Antioxidant Activity of Peptides Derived from Egg White Proteins by Enzymatic Hydrolysis. J. Food Prot. 2004, 67, 1939-1944.
35. Cheung, I.W.Y.; Nakayama, S.; Hsu, M.N.K.; Samaranayaka, A.G.P.; Li-Chan, E.C.Y. Angiotensin-I Converting Enzyme Inhibitory Activity of Hydrolysates from Oat (Avena Sativa) Proteins by in Silico and in Vitro Analyses. J. Agric. Food Chem. 2009, 57, 9234-9242.
36. Miguel, M.; Recio, I.; Gomez-Ruiz, J.A.; Ramos, M.; Lopez-Fandino, R. Angiotensin I-Converting Enzyme Inhibitory Activity of Peptides Derived from Egg White Proteins by Enzymatic Hydrolysis. J. Food Prot. 2004, 67, 1914-1920.
37. Maeno, M.; Yamamoto, N.; Takano, T. Identification of an Antihypertensive Peptide from Casein Hydrolysate Produced by a Proteinase from Lactobacillus Helveticus CP790. J. Dairy Sci. 1996, 79, 1316-1321.
38. Hideaki, K.; Kunio, D.; Shigeru, S.; Hideyo, U.; Ryuji, S.; Umeji, M.; Shizume, T. Antihypertensive Effect of Tryptic Hydrolysate of Milk Casein in Spontaneously Hypertensive Rats. Comp. Biochem. Physiol. Part C Comp. Pharmacol. 1990, 96, 367-371.
39. Marques, C.; Amorim, M.M.; Pereira, J.O.; Pintado, M.E.; Moura, D.; Calhau, C.; Pinheiro, H. Bioactive Peptides: Are there More Antihypertensive Mechanisms Beyond ACE Inhibition? Curr. Pharm. Des. 2012, 18, 4706-4713.
40. Udenigwe, C.C.; Mohan, A. Mechanisms of Food Protein-Derived Antihypertensive Peptides Other than ACE Inhibition. J. Funct. Foods 2014, 8, 45-52.
41. Siro, I.; Kapolna, E.; Kapolna, B.; Lugasi, A. Functional Food. Product Development, Marketing and Consumer Acceptance—A Review. Appetite 2008, 51, 456-467.
42. Matsui, T.; Tanaka, M. Antihypertensive Peptides and Their Underlying Mechanisms; Anonymous, Ed.; Wiley-Blackwell: Oxford, UK, 2010; pp. 43-54.
43. Viera, A.J.; Neutze, D.M. Diagnosis of Secondary Hypertension: An Age-Based Approach. Am. Fam. Phys. 2010, 82, 1471-1478.
44. Carretero, O.A.; Oparil, S. Essential Hypertension: Part I: Definition and Etiology. Circulation 2000, 101, 329-335.
45. Schulz, E.; Gori, T.; Munzel, T. Oxidative Stress and Endothelial Dysfunction in Hypertension. Hypertens. Res. 2011, 34, 665-673.
46. Paravicini, T.M.; Touyz, R.M. Redox Signaling in Hypertension. Cardiovasc. Res. 2006, 71, 247-258.
47. Cuzzocrea, S.; Mazzon, E.; Dugo, L.; di Paola, R.; Caputi, A.P.; Salvemini, D. Superoxide: A Key Player in Hypertension. FASEB J. 2004, 18, 94-101.
48. Intengan, H.D.; Schiffrin, E.L. Vascular Remodeling in Hypertension: Roles of Apoptosis, Inflammation, and Fibrosis. Hypertension 2001, 38, 581-587.
49. Hall, J.E.; Granger, J.P.; do Carmo, J.M.; da Silva, A.A.; Dubinion, J.; George, E.; Hamza, S.; Speed, J.; Hall, M.E. Hypertension: Physiology and Pathophysiology. Comp. Physiol. 2012, 2, 2393-2442.
50. Foëx, P.; Sear, J. Hypertension: Pathophysiology and Treatment. Continuing Education in Anaesthesia. Crit. Care Pain 2004, 4, 71-75.
51. Beevers, G.; Lip, G.Y.H.; O’Brien, E. The Pathophysiology of Hypertension. BMJ 2001, 322, 912-916.
52. Oparil, S.; Haber, E. The Renin-Angiotensin System. N. Engl. J. Med. 1974, 291, 389-401.
53. Zhuo, J.L.; Ferrao, F.M.; Zheng, Y.; Li, X.C. New Frontiers in the Intrarenal Renin-Angiotensin System: A Critical Review of Classical and New Paradigms. Front. Endocrinol. (Lausanne) 2013, 4, 166.
54. Bader, M.; Ganten, D. Update on Tissue Renin-Angiotensin Systems. J. Mol. Med. 2008, 86, 615-621.
55. Michel, J.B. Renin-Angiotensin System and Vascular Remodelling. Med. Sci. (Paris) 2004, 20, 409-413.
56. Sriramula, S.; Cardinale, J.P.; Lazartigues, E.; Francis, J. ACE2 Overexpression in the Paraventricular Nucleus Attenuates Angiotensin II-Induced Hypertension. Cardiovasc. Res. 2011, 92, 401-408.
57. Liu, K.L. Regulation of Renal Medullary Circulation by the Renin-Angiotensin System in Genetically Hypertensive Rats. Clin. Exp. Pharmacol. Physiol. 2009, 36, 455-461.
58. Millatt, L.J.; Abdel-Rahman, E.M.; Siragy, H.M. Angiotensin II and Nitric Oxide: A Question of Balance. Regul. Pept. 1999, 81, 1-10.
59. Stankevicius, E.; Kevelaitis, E.; Vainorius, E.; Simonsen, U. Role of Nitric Oxide and Other Endothelium-Derived Factors. Medicina (Kaunas) 2003, 39, 333-341.
60. Danyel, L.A.; Schmerler, P.; Paulis, L.; Unger, T.; Steckelings, U.M. Impact of AT2-Receptor Stimulation on Vascular Biology, Kidney Function, and Blood Pressure. Integr. Blood Press Control. 2013, 6, 153-161.
61. Nicholls, M. Inhibition of the Renin-Angiotensin System in the Treatment of Heart-Failure—Why, when, and Where. J. Cardiovasc. Pharmacol. 1985, 7, S98-S102.
62. Reaves, P.Y.; Beck, C.R.; Wang, H.W.; Raizada, M.K.; Katovich, M.J. Endothelial-Independent Prevention of High Blood Pressure in L-NAME-Treated Rats by Angiotensin II Type I Receptor Antisense Gene Therapy. Exp. Physiol. 2003, 88, 467-473.
63. Schmaier, A.H. The Kallikrein-Kinin and the Renin-Angiotensin Systems have a Multilayered Interaction. Am. J. Physiol. Regul. Integr. Comp. Physiol. 2003, 285, R1-R13.
64. Behrendt, D.; Ganz, P. Endothelial Function from Vascular Biology to Clinical Applications. Am. J. Cardiol. 2002, 90, 40L-48L.
65. Pober, J.S.; Min, W.; Bradley, J.R. Mechanisms of Endothelial Dysfunction, Injury, and Death. Annu. Rev. Pathol. Mech. Dis. 2009, 4, 71-95.
66. Aroor, A.R.; Demarco, V.G.; Jia, G.; Sun, Z.; Nistala, R.; Meininger, G.A.; Sowers, J.R. The Role of Tissue Renin-Angiotensin-Aldosterone System in the Development of Endothelial Dysfunction and Arterial Stiffness. Front. Endocrinol. (Lausanne) 2013, 4, 161.
67. Zhang, H.; Park, Y.; Wu, J.; Chen, X.; Lee, S.; Yang, J.; Dellsperger, K.C.; Zhang, C. Role of TNF-Alpha in Vascular Dysfunction. Clin. Sci. (Lond.) 2009, 116, 219-230.
68. Capettini, L.S.; Cortes, S.F.; Lemos, V.S. Relative Contribution of eNOS and nNOS to Endothelium-Dependent Vasodilation in the Mouse Aorta. Eur. J. Pharmacol. 2010, 643, 260-266.
69. Forstermann, U.; Sessa, W.C. Nitric Oxide Synthases: Regulation and Function. Eur. Heart J. 2012, 33, 829-837, 837a-837d.
70. Cohen, R.A.; Vanhoutte, P.M. Endothelium-Dependent Hyperpolarization. Beyond Nitric Oxide and Cyclic GMP. Circulation 1995, 92, 3337-3349.
71. Sudano, I.; Spieker, L.E.; Hermann, F.; Flammer, A.; Corti, R.; Noll, G.; Luscher, T.F. Protection of Endothelial Function: Targets for Nutritional and Pharmacological Interventions. J. Cardiovasc. Pharmacol. 2006, 47 (Suppl. S2), S136-S150; discussion S172-S176.
72. Pennathur, S.; Heinecke, J.W. Oxidative Stress and Endothelial Dysfunction in Vascular Disease. Curr. Diabetes Rep. 2007, 7, 257-264.
73. Nathan, C.; Xie, Q.W. Regulation of Biosynthesis of Nitric Oxide. J. Biol. Chem. 1994, 269, 13725-13728.
74. Barton, M.; Yanagisawa, M. Endothelin: 20 Years from Discovery to Therapy. Can. J. Physiol. Pharmacol. 2008, 86, 485-498.
75. Bourque, S.L.; Davidge, S.T.; Adams, M.A. The Interaction between Endothelin-1 and Nitric Oxide in the Vasculature: New Perspectives. Am. J. Physiol. Regul. Integr. Comp. Physiol. 2011, 300, R1288-R1295.
76. Alonso, D.; Radomski, M. The Nitric Oxide-Endothelin-1 Connection. Heart Fail. Rev. 2003, 8, 107-115.
77. Mark, A.L. The Sympathetic Nervous System in Hypertension: A Potential Long-Term Regulator of Arterial Pressure. J. Hypertens. Suppl. 1996, 14, S159-S165.
78. Tsuru, H.; Tanimitsu, N.; Hirai, T. Role of Perivascular Sympathetic Nerves and Regional Differences in the Features of Sympathetic Innervation of the Vascular System. Jpn. J. Pharmacol. 2002, 88, 9-13.
79. Currie, G.; Freel, E.M.; Perry, C.G.; Dominiczak, A.F. Disorders of Blood Pressure Regulation-Role of Catecholamine Biosynthesis, Release, and Metabolism. Curr. Hypertens. Rep. 2012, 14, 38-45.
80. Prabhakar, N.R.; Peng, Y.J.; Kumar, G.K.; Nanduri, J.; di Giulio, C.; Lahiri, S. Long-Term Regulation of Carotid Body Function: Acclimatization and Adaptation—Invited Article. Adv. Exp. Med. Biol. 2009, 648, 307-317.
81. Renna, N.F.; de Las Heras, N.; Miatello, R.M. Pathophysiology of Vascular Remodeling in Hypertension. Int. J. Hypertens. 2013, 2013, 808353.
82. Giannotti, G.; Landmesser, U. Endothelial Dysfunction as an Early Sign of Atherosclerosis. Herz 2007, 32, 568-572.
83. Cheng, Z.J.; Vapaatalo, H.; Mervaala, E. Angiotensin II and Vascular Inflammation. Med. Sci. Monit. 2005, 11, RA194-RA205.
84. Visse, R.; Nagase, H. Matrix Metalloproteinases and Tissue Inhibitors of Metalloproteinases: Structure, Function, and Biochemistry. Circ. Res. 2003, 92, 827-839.
85. Schmid-Schönbein, G.W. Matrix Metalloproteinases Activities in Hypertension: Emerging Opportunities. Hypertension 2011, 57, 24-25.
86. Yasmin, Wallace, S.; McEniery, C.M.; Dakham, Z.; Pusalkar, P.; Maki-Petaja, K.; Ashby, M.J.; Cockcroft, J.R.; Wilkinson, I.B. Matrix Metalloproteinase-9 (MMP-9), MMP-2, and Serum Elastase Activity are Associated with Systolic Hypertension and Arterial Stiffness. Arterioscler. Thromb. Vasc. Biol. 2005, 25, 372-378.
87. Cheung, P.Y.; Sawicki, G.; Wozniak, M.; Wang, W.; Radomski, M.W.; Schulz, R. Matrix Metalloproteinase-2 Contributes to Ischemia-Reperfusion Injury in the Heart. Circulation 2000, 101, 1833-1839.
88. Hao, L.; Du, M.; Lopez-Campistrous, A.; Fernandez-Patron, C. Agonist-Induced Activation of Matrix Metalloproteinase-7 Promotes Vasoconstriction through the Epidermal Growth Factor-Receptor Pathway. Circ. Res. 2004, 94, 68-76.
89. Neutel, J.M.; Smith, D.H. Hypertension Management: Rationale for Triple Therapy Based on Mechanisms of Action. Cardiovasc. Ther. 2013, 31, 251-258.
90. Ferreira, S.H.; Bartelt, D.C.; Greene, L.J. Isolation of Bradykinin-Potentiating Peptides from Bothrops Jararaca Venom. Biochemistry 1970, 9, 2583-2593.
91. Ondetti, M.A.; Williams, N.J.; Sabo, E.F.; Pluscec, J.; Weaver, E.R.; Kocy, O. Angiotensin-Converting Enzyme Inhibitors from the Venom of Bothrops Jararaca. Isolation, Elucidation of Structure, and Synthesis. Biochemistry 1971, 10, 4033-4039.
92. Gouda, K.G.M.; Gowda, L.R.; Rao, A.G.A.; Prakash, V. Angiotensin I-Converting Enzyme Inhibitory Peptide Derived from Glycinin, the 11S Globulin of Soybean (Glycine Max). J. Agric. Food Chem. 2006, 54, 4568-4573.
93. Shin, Z.I.; Yu, R.; Park, S.A.; Chung, D.K.; Ahn, C.W.; Nam, H.S.; Kim, K.S.; Lee, H.J. His-His-Leu, an Angiotensin I Converting Enzyme Inhibitory Peptide Derived from Korean Soybean Paste, Exerts Antihypertensive Activity in Vivo. J. Agric. Food Chem. 2001, 49, 3004-3009.
94. Miguel, M.; Manso, M.; Aleixandre, A.; Alonso, M.J.; Salaices, M.; Lopez-Fandino, R. Vascular Effects, Angiotensin I-Converting Enzyme (ACE)-Inhibitory Activity, and Anti Hypertensive Properties of Peptides Derived from Egg White. J. Agric. Food Chem. 2007, 55, 10615-10621.
95. Xu, J.Y.; Qin, L.Q.; Wang, P.Y.; Li, W.; Chang, C. Effect of Milk Tripeptides on Blood Pressure: A Meta-Analysis of Randomized Controlled Trials. Nutrition 2008, 24, 933-940.
96. Boelsma, E.; Kloek, J. IPP-Rich Milk Protein Hydrolysate Lowers Blood Pressure in Subjects with Stage 1 Hypertension, a Randomized Controlled Trial. Nutr. J. 2010, 9, 52.
97. Majumder, K.; Chakrabarti, S.; Morton, J.S.; Panahi, S.; Kaufman, S.; Davidge, S.T.; Wu, J. Egg-Derived Tri-Peptide IRW Exerts Antihypertensive Effects in Spontaneously Hypertensive Rats. PLoS One 2013, 8, e82829.
98. Balti, R.; Bougatef, A.; Guillochon, D.; Dhulster, P.; Nasri, M.; Nedjar-Arroume, N. Changes in Arterial Blood Pressure After Single Oral Administration of Cuttlefish (Sepia Officinalis) Muscle Derived Peptides in Spontaneously Hypertensive Rats. J. Funct. Foods 2012, 4, 611-617.
99. Miguel, M.; Gomez-Ruiz, J.A.; Recio, I.; Aleixandre, A. Changes in Arterial Blood Pressure After Single Oral Administration of Milk-Casein-Derived Peptides in Spontaneously Hypertensive Rats. Mol. Nutr. Food Res. 2010, 54, 1422-1427.
100. Masuda, O.; Nakamura, Y.; Takano, T. Antihypertensive Peptides are Present in Aorta after Oral Administration of Sour Milk Containing these Peptides to Spontaneously Hypertensive Rats. J. Nutr. 1996, 126, 3063-3068.
101. Yamada, A.; Sakurai, T.; Ochi, D.; Mitsuyama, E.; Yamauchi, K.; Abe, F. Novel Angiotensin I-Converting Enzyme Inhibitory Peptide Derived from Bovine Casein. Food Chem. 2013, 141, 3781-3789.
102. Nakamura, Y.; Yamamoto, N.; Sakai, K.; Okubo, A.; Yamazaki, S.; Takano, T. Purification and Characterization of Angiotensin I-Converting Enzyme Inhibitors from Sour Milk. J. Dairy Sci. 1995, 78, 777-783.
103. Nakamura, Y.; Yamamoto, N.; Sakai, K.; Takano, T. Antihypertensive Effect of Sour Milk and Peptides Isolated from it that are Inhibitors to Angiotensin I-Converting Enzyme. J. Dairy Sci. 1995, 78, 1253-1257.
104. Sipola, M.; Finckenberg, P.; Korpela, R.; Vapaatalo, H.; Nurminen, M.L. Effect of Long-Term Intake of Milk Products on Blood Pressure in Hypertensive Rats. J. Dairy Res. 2002, 69, 103-111.
105. Fujita, H.; Yoshikawa, M. LKPNM: A Prodrug-Type ACE-Inhibitory Peptide Derived from Fish Protein. Immunopharmacology 1999, 44, 123-127.
106. Majumder, K.; Wu, J. A New Approach for Identification of Novel Antihypertensive Peptides from Egg Proteins by QSAR and Bioinformatics. Food Res. Int. 2010, 43, 1371-1378.
107. Contreras, F.; de la Parte, M.A.; Cabrera, J.; Ospino, N.; Israili, Z.H.; Velasco, M. Role of Angiotensin II AT1 Receptor Blockers in the Treatment of Arterial Hypertension. Am. J. Ther. 2003, 10, 401-408.
108. Fernandez-Musoles, R.; Castello-Ruiz, M.; Arce, C.; Manzanares, P.; Ivorra, M.D.; Salom, J.B. Antihypertensive Mechanism of Lactoferrin-Derived Peptides: Angiotensin Receptor Blocking Effect. J. Agric. Food Chem. 2014, 62, 173-181.
109. Yu, Z.; Yin, Y.; Zhao, W.; Chen, F.; Liu, J. Antihypertensive Effect of Angiotensin-Converting Enzyme Inhibitory Peptide RVPSL on Spontaneously Hypertensive Rats by Regulating Gene Expression of the Renin-Angiotensin System. J. Agric. Food Chem. 2014, 62, 912-917.
110. He, R.; Maloma S.A.; Girgih, A.T.; Ju, X.; Aluko, R.E. Glycinyl-histidinyl-serine (GHS), a novel rapeseed protein-derived peptide has blood pressure-lowering effect in spontaneously hypertensive rats. J. Agric. Food Chem. 2013, 61, 8396-8402.
111. Ehlers, P.I.; Nurmi, L.; Turpeinen, A.M.; Korpela, R.; Vapaatalo, H. Casein-Derived Tripeptide Ile-Pro-Pro Improves Angiotensin-(1-7)-and Bradykinin-Induced Rat Mesenteric Artery Relaxation. Life Sci. 2011, 88, 206-211.
112. Yamada, Y.; Matoba, N.; Usui, H.; Onishi, K.; Yoshikawa, M. Design of a Highly Potent Anti-Hypertensive Peptide Based on Ovokinin(2-7). Biosci. Biotechnol. Biochem. 2002, 66, 1213-1217.
113. Miguel, M.; Alvarez, Y.; López-Fandiño, R.; Alonso, M.J.; Salaices, M. Vasodilator Effects of Peptides Derived from Egg White Proteins. Regul. Pept. 2007, 140, 131-135.
114. Miguel, M.; Lopez-Fandino, R.; Ramos, M.; Aleixandre, A. Short-Term Effect of Egg-White Hydrolysate Products on the Arterial Blood Pressure of Hypertensive Rats. Br. J. Nutr. 2005, 94, 731-737.
115. Yamaguchi, N.; Kawaguchi, K.; Yamamoto, N. Study of the Mechanism of Antihypertensive Peptides VPP and IPP in Spontaneously Hypertensive Rats by DNA Microarray Analysis. Eur. J. Pharmacol. 2009, 620, 71-77.
116. Sanchez, D.; Kassan, M.; Contreras Mdel, M.; Carron, R.; Recio, I.; Montero, M.J.; Sevilla, M.A. Long-Term Intake of a Milk Casein Hydrolysate Attenuates the Development of Hypertension and Involves Cardiovascular Benefits. Pharmacol. Res. 2011, 63, 398-404.
117. Hirota, T.; Nonaka, A.; Matsushita, A.; Uchida, N.; Ohki, K.; Asakura, M.; Kitakaze, M. Milk Casein-Derived Tripeptides, VPP and IPP Induced NO Production in Cultured Endothelial Cells and Endothelium-Dependent Relaxation of Isolated Aortic Rings. Heart Vessel. 2011, 26, 549-556.
118. Del Mar Contreras, M.; Carron, R.; Montero, M.J.; Ramos, M.; Recio, I. Novel Casein-Derived Peptides with Antihypertensive Activity. Int. Dairy J. 2009, 19, 566-573.
119. Erdmann, K.; Grosser, N.; Schipporeit, K.; Schroder, H. The ACE Inhibitory Dipeptide Met-Tyr Diminishes Free Radical Formation in Human Endothelial Cells Via Induction of Heme Oxygenase-1 and Ferritin. J. Nutr. 2006, 136, 2148-2152.
120. Majumder, K.; Chakrabarti, S.; Davidge, S.T.; Wu, J. Structure and Activity Study of Egg Protein Ovotransferrin Derived Peptides (IRW and IQW) on Endothelial Inflammatory Response and Oxidative Stress. J. Agric. Food Chem. 2013, 61, 2120-2129.
121. Zhao, H.; Usui, H.; Ohinata, K.; Yoshikawa, M. Met-Arg-Trp Derived from Rubisco Lowers Blood Pressure Via Prostaglandin D(2)-Dependent Vasorelaxation in Spontaneously Hypertensive Rats. Peptides 2008, 29, 345-349.
122. Marczak, E.D.; Usui, H.; Fujita, H.; Yang, Y.; Yokoo, M.; Lipkowski, A.W.; Yoshikawa, M. New Antihypertensive Peptides Isolated from Rapeseed. Peptides 2003, 24, 791-798.
123. Yamada, Y.; Ohinata, K.; Lipkowski, A.W.; Yoshikawa, M. Rapakinin, Arg-Ile-Tyr, Derived from Rapeseed Napin, shows Anti-Opioid Activity via the Prostaglandin IP Receptor Followed by the Cholecystokinin CCK(2) Receptor in Mice. Peptides 2011, 32, 281-285.
124. Lüscher, T.F.; Barton, M. Endothelins and Endothelin Receptor Antagonists: Therapeutic Considerations for a Novel Class of Cardiovascular Drugs. Circulation 2000, 102, 2434-2440.
125. Maes, W.; van Camp, J.; Vermeirssen, V.; Hemeryck, M.; Ketelslegers, J.M.; Schrezenmeir, J.; van Oostveldt, P.; Huyghebaert, A. Influence of the lactokinin Ala-Leu-Pro-Met-His-Ile-Arg (ALPMHIR) on the release of endothelin-1 by endothelial cells. Regul. Pept. 2004, 118, 105-109.
126. Fernández-Musoles, R.; López-Díez, J.J.; Torregrosa, G.; Vallés, S.; Alborch, E.; Manzanares, P.; Salom, J.B. Lactoferricin B-Derived Peptides with Inhibitory Effects on ECE-Dependent Vasoconstriction. Peptides 2010, 31, 1926-1933.
127. Fernández-Musoles, R.; Salom, J.B.; Martínez-Maqueda, D.; López-Díez, J.J.; Recio, I.; Manzanares, P. Antihypertensive Effects of Lactoferrin Hydrolyzates: Inhibition of Angiotensinand Endothelin-Converting Enzymes. Food Chem. 2013, 139, 994-1000.
128. Tanaka, M.; Matsui, T.; Ushida, Y.; Matsumoto, K. Vasodilating Effect of Di-Peptides in Thoracic Aortas from Spontaneously Hypertensive Rats. Biosci. Biotechnol. Biochem. 2006, 70, 2292-2295.
129. Matsui, T.; Hayashi, A.; Tamaya, K.; Matsumoto, K.; Kawasaki, T.; Murakami, K.; Kimoto, K. Depressor Effect Induced by Dipeptide, Val-Tyr, in Hypertensive Transgenic Mice is due, in Part, to the Suppression of Human Circulating Renin-Angiotensin System. Clin. Exp. Pharmacol. Physiol. 2003, 30, 262-265.
130. Matsui, T.; Imamura, M.; Oka, H.; Osajima, K.; Kimoto, K.; Kawasaki, T.; Matsumoto, K. Tissue Distribution of Antihypertensive Dipeptide, Val-Tyr, After its Single Oral Administration to Spontaneously Hypertensive Rats. J. Pept. Sci. 2004, 10, 535-545.
131. Tanaka, M.; Tokuyasu, M.; Matsui, T.; Matsumoto, K. Endothelium-independent vasodilation effect of Di-and Tri-peptides in thoracic aorta of sprague-dawley rats. Life Sci. 2008, 82, 869-875.
132. Wang, Z.; Watanabe, S.; Kobayashi, Y.; Tanaka, M.; Matsui, T. Trp-His, a Vasorelaxant Di-Peptide, can Inhibit Extracellular Ca2+ Entry to Rat Vascular Smooth Muscle Cells through Blockade of Dihydropyridine-Like L-Type Ca2+ Channels. Peptides 2010, 31, 2060-2066.
133. Feuerstein, G.; Siren, A.L. The opioid peptides. A role in hypertension? Hypertension 1987, 9, 561-565.
134. Nurminen, M.L.; Sipola, M.; Kaarto, H.; Pihlanto-Leppala, A.; Piilola, K.; Korpela, R.; Tossavainen, O.; Korhonen, H.; Vapaatalo, H. Alpha-lactorphin lowers blood pressure measured by radiotelemetry in normotensive and spontaneously hypertensive rats. Life Sci. 2000, 66, 1535-1543.
135. Sipola, M.; Finckenberg, P.; Vapaatalo, H.; Pihlanto-Leppälä, A.; Korhonen, H.; Korpela, R.; Nurminen, M. Α-Lactorphin and Β-Lactorphin Improve Arterial Function in Spontaneously Hypertensive Rats. Life Sci. 2002, 71, 1245-1253.
136. Aihara, K.; Ishii, H.; Yoshida, M. Casein-Derived Tripeptide, Val-Pro-Pro (VPP), Modulates Monocyte Adhesion to Vascular Endothelium. J. Atheroscler. Thromb. 2009, 16, 594-603.
137. Nakamura, T.; Hirota, T.; Mizushima, K.; Ohki, K.; Naito, Y.; Yamamoto, N.; Yoshikawa, T. Milk-Derived Peptides, Val-Pro-Pro and Ile-Pro-Pro, Attenuate Atherosclerosis Development in Apolipoprotein E-Deficient Mice: A Preliminary Study. J. Med. Food 2013, 16, 396-403.
138. Huang, W.; Chakrabarti, S.; Majumder, K.; Jiang, Y.; Davidge, S.T.; Wu, J. Egg-Derived Peptide IRW Inhibits TNF-α-Induced Inflammatory Response and Oxidative Stress in Endothelial Cells. J. Agric. Food Chem. 2010, 58, 10840-10846.
139. Geleijnse, J.M.; Engberink, M.F. Lactopeptides and Human Blood Pressure. Curr. Opin. Lipidol. 2010, 21, 58-63.
140. Mizushima, S.; Ohshige, K.; Watanabe, J.; Kimura, M.; Kadowaki, T.; Nakamura, Y.; Tochikubo, O.; Ueshima, H. Randomized Controlled Trial of Sour Milk on Blood Pressure in Borderline Hypertensive Men. Am. J. Hypertens. 2004, 17, 701-706.
141. Seppo, L.; Jauhiainen, T.; Poussa, T.; Korpela, R. A Fermented Milk High in Bioactive Peptides has a Blood Pressure-Lowering Effect in Hypertensive Subjects. Am. J. Clin. Nutr. 2003, 77, 326-330.
142. Engberink, M.F.; Schouten, E.G.; Kok, F.J.; van Mierlo, L.A.J.; Brouwer, I.A.; Geleijnse, J.M. Lactotripeptides show no Effect on Human Blood Pressure: Results from a Double-Blind Randomized Controlled Trial. Hypertension 2008, 51, 399-405.
143. Cicero, A.F.G.; Gerocarni, B.; Laghi, L.; Borghi, C. Blood Pressure Lowering Effect of Lactotripeptides Assumed as Functional Foods: A Meta-Analysis of Current Available Clinical Trials. J. Hum. Hypertens. 2011, 25, 425-436.
144. Turpeinen, A.M.; Ikonen, M.; Kivimaki, A.S.; Kautiainen, H.; Vapaatalo, H.; Korpela, R. A Spread Containing Bioactive Milk Peptides Ile-Pro-Pro and Val-Pro-Pro, and Plant Sterols has Antihypertensive and Cholesterol-Lowering Effects. Food Funct. 2012, 3, 621-627.
145. Turpeinen, A.M.; Jarvenpaa, S.; Kautiainen, H.; Korpela, R.; Vapaatalo, H. Antihypertensive Effects of Bioactive Tripeptides-a Random Effects Meta-Analysis. Ann. Med. 2013, 45, 51-56.
146. Hirota, T.; Ohki, K.; Kawagishi, R.; Kajikoto, Y.; Mizuno, S.; Nakamura, Y.; Kitakaze, M. Casein Hydrolysate Containing the Antihypertensive Tripeptides Val-Pro-Pro and Ile-Pro-Pro improves Vascular Endothelial Function Independent of Blood Pressure-Lowering Effects: Contribution of the Inhibitory Action of Angiotensin-Converting Enzyme. Hypertens. Res. 2007, 30, 489-496.
147. Li, H.; Prairie, N.; Udenigwe, C.C.; Adebiyi, A.P.; Tappia, P.S.; Aukema, H.M.; Jones, P.J.; Aluko, R.E. Blood Pressure Lowering Effect of a Pea Protein Hydrolysate in Hypertensive Rats and Humans. J. Agric. Food Chem. 2011, 59, 9854-9860.
148. Kawasaki, T.; Seki, E.; Osajima, K.; Yoshida, M.; Asada, K.; Matsui, T.; Osajima, Y. Antihypertensive Effect of Valyl-Tyrosine, a Short Chain Peptide Derived from Sardine Muscle Hydrolyzate, on Mild Hypertensive Subjects. J. Hum. Hypertens. 2000, 14, 519-523.
149. Kawasaki, T.; Jun, C.J.; Fukushima, Y.; Kegai, K.; Seki, E.; Osajima, K.; Itoh, K.; Matsui, T.; Matsumoto, K. Antihypertensive Effect and Safety Evaluation of Vegetable Drink with Peptides Derived from Sardine Protein Hydrolysates on Mild Hypertensive, High-Normal and Normal Blood Pressure Subjects. Fukuoka Igaku Zasshi 2002, 93, 208-218.
150. Matsui, T.; Tamaya, K.; Seki, E.; Osajima, K.; Matsumo, K.; Kawasaki, T. Absorption of Val-Tyr with in Vitro Angiotensin I-Converting Enzyme Inhibitory Activity into the Circulating Blood System of Mild Hypertensive Subjects. Biol. Pharm. Bull. 2002, 25, 1228-1230.
151. Flack, J.M.; Ference, B.A.; Levy, P. Should African Americans with Hypertension be Treated Differently than non-African Americans? Curr. Hypertens. Rep. 2014, 16, 1-6.
152. Ferdinand, K.C.; Nasser, S.A. A Review of the Efficacy and Tolerability of Combination Amlodipine/Valsartan in non-White Paitents with Hypertension. Am. J. Cardiovasc. Drugs 2013, 13, 301-313.
153. Cicero, A.F.; Rosticci, M.; Gerocarni, B.; Bacchelli, S.; Veronesi, M.; Strocchi, E.; Borghi, C. Lactotripeptides Effect on Office and 24-H Ambulatory Blood Pressure, Blood Pressure Stress Response, Pulse Wave Velocity and Cardiac Output in Patients with High-Normal Blood Pressure or First-Degree Hypertension: A Randomized Double-Blind Clinical Trial. Hypertens. Res. 2011, 34, 1035-1040.
154. Kuba, K.; Imai, Y.; Ohto-Nakanishi, T.; Penninger, J.M. Trilogy of ACE2: A Peptidase in the Renin-Angiotensin System, a SARS Receptor, and a Partner for Amino Acid Transporters. Pharmacol. Ther. 2010, 128, 119-128.